Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China

Abstract

The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma.The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS-CoV-2 in throat This article is protected by copyright. All rights reserved. Accepted Articleswab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-art therapy during COVID-19 pandemic crisis.

Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas

“…treat severe COVID-19 have recently been published [18][19][20][21][22] and the overall findings presented herein are consistent with these reports.…”

“…18 Two additional small case studies of five and six patients have since been published with similar findings. 20,21 A more recent study by Zeng et. al.…”

“…17 Several small observational studies published during the COVID-19 pandemic suggest convalescent plasma is part of an effective treatment strategy for patients with severe disease. [18][19][20][21] The first report describing administration of convalescent plasma to five patients early in the COVID-19 outbreak in Wuhan was recently published. 19 Five critically ill patients received two, same-day infusions from five recovered healthy donors.…”

The role of passive immunization in the age of SARS-CoV-2: an update

“…In this case study, the convalescent plasma infusions were well tolerated also. Five patients with radiological lung finding (4 oxygenized) recovered and were PCR negative or discharged after 4-10 days after plasma infusion [10]. Interestingly in the 6th patient with only mild symptoms for more than 30 days the positive PCR throat swab findings could be cleared after plasma infusion.…”

“…Meanwhile there a several publications, which show that the renaissance of passive immunization could be a bridging technology until effective medications or an active immunization is available. [2][3][4][5][6][7][8][9][10].…”